NOV 13, 2018 07:46 AM PST

Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful

WRITTEN BY: Nouran Amin

Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures, and cognitive disabilities. These symptoms are due to an impaired ability to properly metabolize cholesterol.

Seeking treatment for NPC, a recent drug was placed in a key clinical trial for 56 affected children and youth. The drug, VTS-270, brought disappointing results when it was found to perform no differently than the placebo and “did not show a statistically significant separation,” says Steven Romano, the executive vice president of Mallinckrodt Pharmaceutical and chief scientific officer. However, the condition did not progress in both groups during the 1-year study.

“But importantly, neither did [patients in the active or placebo arms of the trial] show disease progression as would have been anticipated in the neurodegenerative condition over 52 weeks of observation,” explains Romano.

VTS-270 consists of a doughnut-shaped sugar molecule called a cyclodextrin that was spinally injected into the cerebrospinal fluid of the brain.

The chemical structure of VT2-270 (2-hydroxypropyl-β-cyclodextrin (HPβCD))

Image Credit: PLOS ONE

The drug showed positive results in animal models of the diseases but not in children during the one year study. Such results prompted other researchers who have expertise in rare diseases to suggest that the trial’s use of a traditional double-blind and randomized controlled trials may not be the best tool in such condition.

“This is a disappointing result but a very important one. The question I have is: Is it truly the case that this agent is not effective, or is the result the consequence of a trial design that in retrospect might have been better?” says Marc Patterson, a child neurologist who has been conducting NPC research and treating NPC-affected children for over 30 years.

Since NPC is a slow progressive disease, Patterson believe that the drug may have been successful if the clinical trial was much longer than the 1-year study. Patterson argues that this particular study raises issues regarding FDA’s approval time in clinical trials involving rare diseases.

“We’ll need to look at those open-label treatment patients and see if there’s any difference that gradually accrues over the course of that additional treatment period,” says Romano.

Source: Science Magazine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 20, 2018
Drug Discovery
AUG 20, 2018
Antidepressants Restore Inhibitory Neurons in Mice
The capacity of brain cells to change is referred to as "plasticity” and according to a new study a decline in plasticity is associated with sen...
OCT 06, 2018
Drug Discovery
OCT 06, 2018
New Class of Drugs for Breast Cancer Therapy
Scientists at Stevens Institute of Technology have designed a new class of molecules that may hold the potential to add to the arsenal of drugs actively be...
NOV 05, 2018
Microbiology
NOV 05, 2018
Potential Antidote to Botulism is Found
A microbe called Clostridium botulinum and sometimes two other strains of Clostridium bacteria can make a toxic chemical called botulism....
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Anti-inflammatory Drug Works Like an Inhibitor
At Karolinska Institutet in Sweden, a team of scientists from multiple disciplines have worked together to develop an inflammation inhibitor. The new anti-...
NOV 21, 2018
Drug Discovery
NOV 21, 2018
Drug Could Seek New Approach For Autoimmunity
From a failed pain drug, a protein called ‘BH4’, was recently discovered to have surprising implications in the treatment of autoimmunity and c...
NOV 23, 2018
Cannabis Sciences
NOV 23, 2018
Rimonabant: A Cautionary Tale for Targeting the Endocannabinoid System
The evidence that the endocannabinoid system (ECS) is intimately involved in food intake has been steadily increasing. Thus, in attempts to treat obesity,...
Loading Comments...